Testing two medications together for treatment-resistant T-cell lymphoma

Plain-English translation of NCT06810778 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a combination of two medications— and —in people whose T-cell lymphoma (a blood cancer) has come back or stopped responding to earlier treatments. The study will first figure out the safest and most effective doses of these two medications when given together, then test how well this combination works for patients. If you respond well to the treatment, you may be able to continue taking it for longer than the typical study period.

When T-cell lymphoma comes back after initial treatment or doesn't respond to it, doctors have limited options. This trial is exploring whether combining two medications that work in different ways might help patients whose disease has become resistant to standard therapies.

Do you qualify?

You likely qualify if…

you have been diagnosed with relapsed or refractory T-cell lymphoma (except cutaneous T-cell lymphoma or T-cell-prolymphocytic leukemia)
your lymphoma has gotten worse or come back after at least two previous treatments
you have adequate liver and kidney function based on blood tests
you have adequate blood cell counts (or the study team can help you reach them with supportive care)
you are in reasonably good health and able to manage daily activities (ECOG performance status 0-2)

You likely don't qualify if…

you are a candidate for a stem cell transplant, as doctors would likely recommend that instead
you have previously taken venetoclax or similar PI3K inhibitor medications
you have active infections requiring antibiotics or other untreated, active infections
you have HIV, hepatitis C, or hepatitis B
you had an allogeneic stem cell transplant within the past 6 months or have active graft-versus-host disease

What participation looks like

You would take two medications by mouth at doses that start low and may gradually increase as the study progresses. The study is divided into two phases: in the first phase, researchers carefully test different dose combinations to find the safest and most effective levels; in the second phase, more patients receive the best dose found. You would have regular visits for blood tests and check-ins to monitor how well the treatment is working and watch for any side effects. If you respond well and tolerate the medications, you may continue treatment beyond the typical study period.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(1 site)

United States

David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California